Botulinum Toxin A/Merz
| This is a free, public record extracted from BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets, the only biopharmaceuticals information resource/reference (at www.biopharma.com). You can view partial, truncated product monographs and most indexing terms. For further information about BIOPHARMA, see the description/flyer, published reviews, and the public Products Database and Companies Database. Contact the author/publisher regarding database subscriptions. |
incobotulinumtoxinA - Xeomin; Bocouture; Clostridium botulinum toxin type A; NT 201
Status: approved/marketed in U.S. and Europe
Organizations involved:
Merz GmbH & Co. KGaA – Manuf.; Leerink Swann analyst Seamus Fernandez said in a recent research note that Xeomin poses more of a threat to Medicis' Dysport than to Allergan's Botox. Heavy sampling has helped Merz land about 8% of the botulinium-toxin market, Fernandez wrote in a subsequent note. But, according to Xeomin's label, Merz's drug can iron out wrinkles for up to three months, while Botox's smoothing effects last up to four months.
R&D; Tech.; Europe mark.
Allergan, Inc. – Patent dispute
Cross ref: See the entries above for Botulinum Toxin Products and Botulinum Toxin A (BOTOX).
Description: Xeomin is a lyophilized (freeze-dried) formulation of botulinum toxin type A free of complexing proteins manufactured by culture of Clostridium botulinum, Hall strain bacteria. The botulinum toxin complex is purified from the culture supernatant and then the active ingredient is chromatographically separated from the proteins (hemaglutinins and non-hemaglutinins) through a series of steps yielding the active neurotoxin without accessory protei
... truncated (just the beginning)
Annual sales (2008; $million): (reserved for subscribers)
Annual sales (2009; $million): (reserved for subscribers)
Annual sales (2010; $million): (reserved for subscribers)
Annual sales (2011; $million): (reserved for subscribers)
Annual sales (2012; $million): (reserved for subscribers)
Index Terms:
Companies involvement:
Partial monograph text:
603 Botulinum Toxin A/Merz
Nomenclature:
Botulinum Toxin A/Merz [BIO]
Xeomin [TR]
incobotulinumtoxinA [USAN]
Bocouture [TR For; in Germany, the United Kingdom, France, Italy and Spain]
Botulinum Toxin A [CAS]
93384-43-1 [CAS RN]
Clostridium botulinum toxin type A [SY]
NT 201 [SY]
NDC 0259-1605-01 and NDC 0259-1610-01 [NDC]
FDA Class: Biologic BLA
Year of approval (FDA) = 2010
Annual sales (2007; $million): (reserved for subscribers)
Biosimilars/biobetters Data
U.S.A.
European Union (EU)
Biosimilars/biobetters-related U.S. Patents: Reserved for subscribers]
U.S. Patent Expiration Year: Reserved for subscribers
U.S. Biosimilars Data Exclusivity Expiration: Reserved for subscribers
U.S. Biosimilars Orphan Exclusivity Expiration: Reserved for subscribers
U.S. Biosimilars Launchability Year: Reserved for subscribers
U.S. Biobetters Launchability Year: Reserved for subscribers
Biosimilars/biobetters-related EU Patents: Reserved for subscribers
EU Patent Expiration Year: Reserved for subscribers
EU Biosimilars Data Exclusivity Expiration: Reserved for subscribers
EU Biosimilars Orphan Exclusivity Expiration: Reserved for subscribers
EU Biosimilars Launchability Year: Reserved for subscribers
EU Biobetters Launchability Year: Reserved for subscribers
biopharmaceutical products
toxins (see also toxoids)
Clostridium botulinum
acetylcholine
Albumin (Human)
lyophilized (freeze-dried)
sucrose
apheresis (hemapheresis)
North American coral snake
North American coral snake
EU200 Currently Approved in EU
UM001 Marketed Product in US
US200 Currently Approved in US
EM001 Marketed Product in EU
Copyright© 2018, Biotechnology Information Institute